The Hazelden Betty Ford Foundation has signed an agreement with Mayo Clinic to collaborate on a federally funded research project that could help usher in a new era of addiction medicine. The two national health care leaders will search for genetic markers that predict response to the drug, Acamprosate, which has been shown to help people with alcohol use disorder stay sober.
The five-year study, coordinated with and funded by grants from the National Institute on Alcohol Abuse and Alcoholism, aims to help addiction care provider organizations understand who, based on a blood test, should receive the medicine and who shouldn’t based on their likelihood to experience side effects or be nonresponsive. Researchers also hope to uncover insights that could lead to new medications and potentially help predict who is most vulnerable to problematic drinking.
The U.S. Food and Drug Administration has approved three medications for the treatment of alcohol use disorder. However, they do not work for everyone, and there are no known biomarkers to reliably predict which consumers would be good candidates for these therapies.
Researchers will recruit 800 people receiving care for alcohol use disorder at Mayo Clinic-affiliated treatment programs in Rochester and Albert Lea as well as at Hazelden Betty Ford in Center City, a large campus that includes residential treatment services and embedded researchers. Study participants will provide blood for genetic testing that will identify variants to help predict their response to the use of Acamprosate or a placebo. The study, which is also supported by funding from the Samuel C. Johnson Genomics of Addiction program, expands upon previous research completed by Mayo Clinic.
The Hazelden Betty Ford Foundation is a force of healing and hope for individuals, families, and communities affected by addiction to alcohol and other drugs. As the nation’s leading non-profit provider of comprehensive inpatient and outpatient treatment for adults and youth, the Foundation has 17 locations nationwide and collaborates with an expansive network throughout health care. With a legacy that began in 1949 and includes the 1982 founding of the Betty Ford Center, the Foundation today also encompasses a graduate school of addiction studies, a publishing division, an addiction research center, recovery advocacy and thought leadership, professional and medical education programs, school-based prevention resources, and a specialized program for children who grow up in families with addiction.
Mayo Clinic is the first and largest integrated, non-profit medical group practice in the world. Clinical professionals from every medical specialty work together to care for consumers, joined by common systems and a philosophy of the needs of the consumer come first. More than 3,800 physicians and scientists and 50,900 allied health staff work at Mayo Clinic. Mayo Clinic also serves over 70 communities through Mayo Clinic Health System with locations in Minnesota, Iowa, and Wisconsin. Collectively, these locations care for more than 1 million people each year.
This was reported by the Hazelden Betty Ford Foundation on July 30, 2019.
Contact information: Jeremiah Gardner, Director, Communications and Public Affairs, Hazelden Betty Ford Foundation, Post Office Box 11, 15251 Pleasant Valley Road, Center City, Minnestota 55012; 651-213-4231; Email: firstname.lastname@example.org; Website: www.hazeldenbettyford.org
Contact information: Mayo Clinic, 200 First Street South West, Rochester, Minnesota 55905; 507-284-2511; Website: www.mayoclinic.org